Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
We believe these data underscore the potential of CagriSema to address unmet medical needs in obesity and support long-term disease management." The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomized, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 ) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomized, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 )
No clinical data currently support use in humans for arthritis
She is one of India's highest-paid actresses
Liver histopathology was examined by a blinded pathologist
4 Clinical studies of exercise interventions in neurodegenerative diseases Exercise, as a low-cost and highly accessible non-pharmacological intervention, has received growing attention for the prevention and treatment of NDDs (Sanaeifar et al., 2024)
